{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:16:15Z","timestamp":1777972575695,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00277-023-05342-y","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T05:02:12Z","timestamp":1689224532000},"page":"3125-3132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia"],"prefix":"10.1007","volume":"102","author":[{"given":"Naveen C","family":"Hegde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaweta","family":"Kaundal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lekha","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Prinja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-2796","authenticated-orcid":false,"given":"Amol N","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"issue":"1","key":"5342_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao Y, Lin X, Li F, Jin J, Wang H (2022) The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online 21(1):4","journal-title":"Biomed Eng Online"},{"key":"5342_CR2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/GO.20.00032","volume":"6","author":"V Tejaswi","year":"2020","unstructured":"Tejaswi V, Lad DP, Jindal N, Prakash G, Malhotra P, Khadwal A et al (2020) Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol 6:866\u2013872","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"5342_CR3","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/curroncol29050293","volume":"29","author":"Z Todorovic","year":"2022","unstructured":"Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P et al (2022) CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Curr Oncol 29(5):3647\u20133657","journal-title":"Curr Oncol"},{"issue":"3","key":"5342_CR4","doi-asserted-by":"publisher","first-page":"e1002759","DOI":"10.1371\/journal.pmed.1002759","volume":"16","author":"BJ Angell","year":"2019","unstructured":"Angell BJ, Prinja S, Gupt A, Jha V, Jan S (2019) The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana and the path to universal health coverage in India: overcoming the challenges of stewardship and governance. PLoS Med 16(3):e1002759","journal-title":"PLoS Med"},{"issue":"3","key":"5342_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.4103\/jfmpc.jfmpc_1789_20","volume":"10","author":"GVVP Sriee","year":"2021","unstructured":"Sriee GVVP, Maiya GR (2021) Coverage, utilization, and impact of Ayushman Bharat scheme among the rural field practice area of Saveetha Medical College and Hospital, Chennai. J Family Med Prim Care 10(3):1171\u20131176","journal-title":"J Family Med Prim Care"},{"issue":"6","key":"5342_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/ejh.13503","volume":"105","author":"P Youron","year":"2020","unstructured":"Youron P, Singh C, Jindal N, Malhotra P, Khadwal A, Jain A et al (2020) Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire. Eur J Haematol 105(6):755\u2013762","journal-title":"Eur J Haematol"},{"issue":"2","key":"5342_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12288-020-01378-6","volume":"37","author":"C Singh","year":"2021","unstructured":"Singh C, Jindal N, Youron P, Malhotra P, Prakash G, Khadwal A et al (2021) Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients. Indian J Hematol Blood Transfus 37(2):313\u2013317","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"5342_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A et al (2020) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 34(3):787\u2013798","journal-title":"Leukemia."},{"issue":"7","key":"5342_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928\u2013942","journal-title":"Lancet Oncol"},{"issue":"12","key":"5342_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101\u20131110","journal-title":"N Engl J Med"},{"key":"5342_CR11","unstructured":"India GDP per capita (2021) StatisticsTimes.com [Internet]. [Cited 2023 Apr 27].\u00a0\u00a0https:\/\/statisticstimes.com\/economy\/country\/india-gdp-per-capita.php"},{"issue":"8","key":"5342_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-8-32","volume":"20","author":"CR Blankart","year":"2013","unstructured":"Blankart CR, Koch T, Linder R, Verheyen F, Schrey\u00f6gg J, Stargardt T (2013) Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis 20(8):32","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"5342_CR13","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1080\/03007995.2020.1835851","volume":"36","author":"Q Huang","year":"2020","unstructured":"Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M et al (2020) Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. Curr Med Res Opin 36(12):2009\u20132018","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"5342_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","volume":"19","author":"B Emond","year":"2019","unstructured":"Emond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A (2019) Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy. Clin Lymphoma Myeloma Leuk 19(12):763\u2013775.e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5342_CR15","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/GO.20.00012","volume":"6","author":"V Sathyanarayanan","year":"2020","unstructured":"Sathyanarayanan V, Flowers CR, Iyer SP (2020) Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States. JCO Glob Oncol 6:1124\u20131133","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"5342_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1470-2045(17)30062-1","volume":"18","author":"B Mikudina","year":"2017","unstructured":"Mikudina B, Goodall M, Adler AI (2017) NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation. Lancet Oncol 18(3):289\u2013290","journal-title":"Lancet Oncol"},{"issue":"15","key":"5342_CR17","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","volume":"2","author":"JI Barnes","year":"2018","unstructured":"Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK et al (2018) Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv 2(15):1946\u20131956","journal-title":"Blood Adv"},{"issue":"2","key":"5342_CR18","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.clml.2017.12.005","volume":"18","author":"R Sinha","year":"2018","unstructured":"Sinha R, Redekop WK (2018) Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom. Clin Lymphoma Myeloma Leuk 18(2):e131\u2013e142","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5342_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.jval.2022.04.001","volume":"25","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I (2022) Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia. Value Health 25(10):1685\u20131695","journal-title":"Value Health"},{"issue":"12","key":"5342_CR20","doi-asserted-by":"publisher","first-page":"1033413","DOI":"10.3389\/fonc.2022.1033413","volume":"21","author":"A Visentin","year":"2022","unstructured":"Visentin A, Mauro FR, Catania G, Fresa A, Vitale C, Sanna A et al (2022) Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study. Front Oncol 21(12):1033413. https:\/\/doi.org\/10.3389\/fonc.2022.1033413 PMID: 36479077; PMCID: PMC9719965","journal-title":"Front Oncol"},{"key":"5342_CR21","doi-asserted-by":"crossref","unstructured":"Nehra P, Chauhan AS, Malhotra P, Kumar L, Singh A, Gupta N, et al (2023) Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India. Lancet Reg Health Southeast Asia 13,100201 [Accessed on 20-07-2023 from.\u00a0https:\/\/www.thelancet.com\/journals\/lansea\/article\/PIIS2772-3682(23)00061-6\/fulltext]","DOI":"10.1016\/j.lansea.2023.100201"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05342-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05342-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05342-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:02:20Z","timestamp":1697058140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05342-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5342"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05342-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"20 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}